ELEVATED SERUM LEVELS OF INTERLEUKIN-10 IN PATIENTS WITH METASTATIC MALIGNANT-MELANOMA

被引：121

作者：

DUMMER, W

BECKER, JC

SCHWAAF, A

LEVERKUS, M

MOLL, T

BROCKER, EB

机构：

[1] Department of Dermatology, University of Würzburg, Würzburg, 97080

来源：

MELANOMA RESEARCH | 1995年 / 5卷 / 01期

关键词：

D O I：

10.1097/00008390-199502000-00008

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Interleukn-10 (IL-10), originally described as a product of TH2 cell clones, has been recognized as a potential immunosuppressive cytokine. To investigate the relevance of IL-10 in melanoma patients in vivo, we studied IL-10 serum levels in 104 untreated patients in different stages of the disease; 20 healthy subjects and 22 patients with inflammatory dermatoses served as controls. Serum levels were measured by ELISA. Only one of 31 patients with stage I melanoma (3%) and one of 16 stage II patients (6%) showed detectable IL-10 levels. Interestingly, six of 17 patients with lymph node metastases (stage III, 35%) and 29 of 40 patients with wide-spread disease (stage IV, 73%) revealed IL-10 levels of 15-480 pg/ml. No healthy person and only one control patient had a detectable IL-10 serum level. The data suggest that IL-10 in melanoma patients may contribute to down-modulation of anti-tumour responses in vivo.

引用

页码：67 / 68

页数：2

共 10 条

[1]

Fiorentino D.F., Bond M.W., Mosmann T.R., Two types of mouse T helper cells. IV. Th2 clones secrete a factor that inhibits cytokine production by Th 1 clones, J Exp Med, 170, pp. 2081-2095, (1989)

[2]

dewaal Malefyt R., Haanen J., Spits H., Et al., Interleukin 10 and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression, J Exp Med, 174, pp. 915-924, (1991)

[3]

Ding L., Linsley P., Huang L.Y., Et al., IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression, J Immunol, 151, pp. 1224-1234, (1993)

[4]

Dewaal Malefyt R., Yssel H., Devries J.E., Direct effect of IL-10 on subsets of human CD4+ T cell clones and resting T cells, J Immunol, 150, pp. 4754-4765, (1993)

[5]

Becker J.C., Czerny C., Brocker E.B., Maintenance of clonal anergy by endogenously produced IL-10, Int Immunol, (1995)

[6]

Bacchetta R., Bigler M., Touraine J.L., Et al., High levels of IL-10 production in vivo are associated with tolerance in SCID patients transplanted with HLA mismatched hematopoietic stem cells, J Exp Med, 179, pp. 493-502, (1994)

[7]

Marchant A., Deviere J., Byl B., Et al., Interleukin-10 production during septicemia, Lancet, 343, pp. 707-708, (1994)

[8]

Merville P., Rousset F., Banchereau J., Et al., Serum interleukin-10 in early stage multiple myeloma, Lancet, 340, pp. 1544-1545, (1992)

[9]

Blay J., Burdin N., Rousset F., Et al., Serum interleukin-10 in non-hodgkin’s lymphoma: A prognostic factor, Blood, 82, pp. 2169-2174, (1993)

[10]

Chen Q., Daniel V., Maher D., Et al., Production of IL-10 by melanoma cells: Examination of its role in immunosuppression mediated by melanoma, Int J Cancer, 56, pp. 755-760, (1994)

← 1 →